UCI 趙 Chao Family Comprehensive Cancer Center




# Gynecology Oncology (GynOnc) Disease-Oriented Team

## Clinical Research Treatment Trial Flowchart

# Ovarian

## PLATINUM-SENSITIVE

**UCI 26-14**
Raludotatug Deruxtecan
High-Grade Serous
Cohort A-2 2L
Cohort D 2L PARPi progressor
PI: Tewari
CRC: TBA

Accrual: 0/5

**GOG-3136**
GSK5733584 + Bevacizumab Vs. Platinum doublet + Bevacizumab

PI: Tewari
CRC: TBA

Accrual: 0/5

## NEWLY DIAGNOSED

**UCI 26-68**
Intraoperative Tumor Fluorescence + Cytalux

PI: Tseng
CRC: TBA

Accrual: 0/3

# Ovarian – 1st line maintenance

Open to Accrual | Low Accruing | Pending Activation/Suspended

## NEWLY DIAGNOSED

**GOG-3135**
GSK5733584 +/- Bevacizumab Maintenance
HR proficient
PI: Tewari
CRC: TBA

Accrual: 0/5

**NRG-GY036**
Olaparib +/- Bevacizumab Maintenance
BRCA 1/2 or HRD +
PI: Dwabe
CRC: TBA

Accrual: 0/7

**GOG-3146**
INCB123667
Cyclin E1

PI: Tewari
CRC: TBA

Accrual: 0/5

Open to Accrual | Low Accruing | Pending Activation/Suspended

## PLATINUM-RESISTANT

**GOG-3076**
Platinum Doublet + Bevacizumab +/-OlviVec
>3L
PI: Tewari
CRC: Jiana Ejbara

Accrual: 5/8

**UCI 26-14**
Cohort B2: Raludotatug Deruxtecan + Bev
1-3 prior lines
PI: Tewari
CRC: TBA

Accrual: 0/5

Open to Accrual | Low Accruing | Pending Activation/Suspended

# Cervical

## NEWLY DIAGNOSED

**NRG-GY037**
Chemoradiation with pembro, followed by pembro maintenance +/- induction therapy of chemo & pembro
No prior treatment
PI: Healy
CRC: Jiana Ejbara

Accrual: 3/5

## NEWLY DIAGNOSED/RECURRENT/PERSISTENT

**GOG-3123**
Sacituzumab Tirumotecan + Pembrolizumab +/- Bevacizumab VS. SOC
1L (6 cycles) Maintenance
PI: Tewari
CRC: Jiana Ejbara

Accrual: 0/5

# Endometrial

**GOG 3119**
Pembro +/- Sacituzumab Tirumotecan
For pMMR
1L or 1 prior
PI: Tseng
CRC: Jiana Ejbara

Accrual: 4/10

**GOG 3110**
AZD8205 (ADC) vs. Physicians Choice for B7-H4 positive endo
≤ 2 prior lines

PI: Tseng
CRC: Jiana Ejbara

Accrual: 0/5

**GOG 3128**
Rinatabart Sesutecan
≤ 3 prior lines

PI: Tewari
CRC: TBA

Accrual: 0/6

# Basket Trials

Open to Accrual | Low Accruing | Pending Activation/Suspended

**UCI 24-146**
REGN5668 + REGN4018 or Cemiplimab
Endometrial or ovarian (SLOT RSVP REQ)
PI: Tseng
CRC: Jiana Ejbara

Accrual: 2/5

**UCI 24-142**
VET3-TGI +/- Atezolizumab
PI: Uchio
CRC: Jiana Ejbara

Accrual: 3/4

**UCI 24-08**
SPEDOX-6 for 2L+ cervical, uterine or ovarian
SLOT RSVP REQ
PI: Chow
CRC: Jiana Ejbara

Accrual: 9/67

**UCI 24-176**
Raludotatug Deruxtecan
Endometrial, Ovarian, & Cervical
SLOT RSVP REQ
PI: Mar
CRC: Jiana Ejbara

Accrual: 0/5

# Basket Trials

Open to Accrual | Low Accruing | Pending Activation/Suspended

**UCI 26-60**
ASP546C
CLDN18.2

PI: Dayyani
CRC: TBA

Accrual: 0/10

**UCI 25-194**
PLX-61639
SMARCA4

PI: Villalona-Calero
CRC: Jiana Ejbara

Accrual: 0/5

# Cognitive Impairment

Open to Accrual | Low Accruing | Pending Activation/Suspended

**Ovarian Cancer**

**UCI 24-05**
Riluzole PO vs. Placebo PO
Perceived worsening of cognitive function
PI: Chan
CRC: Jiana Ejbara

Accrual: 33/59

**UCI 18-120**
N-Acetyl-Cysteine
Chemotherapy-Related Cognitive Impairment
PI: Bota
CRC: Jiana Ejbara

Accrual: 0/12

# Non-Treatment Trials

**UCI 26-87**
CT-DNA
Locally Advanced Cervical Cancer
PI: Hari
CRC: TBA

Accrual: 0/40